Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Fiche publication
Date publication
janvier 2019
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HARLE Alexandre, Dr LEROUX Agnès, Pr MERLIN Jean-Louis, Dr GILSON Pauline
Tous les auteurs :
Franczak C, Dubouis L, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A
Lien Pubmed
Résumé
KRAS and NRAS mutations are identified resistance mutations to anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. BRAF status is also routinely assessed for its poor prognosis value. In our institute, next-generation sequencing (NGS) is routinely used for gene-panel mutations detection including KRAS, NRAS and BRAF, but DNA quality is sometimes not sufficient for sequencing. In our routine practice, Idylla platform is used for the analysis of samples that don't reach sufficient quality criteria for NGS assay.
Référence
PLoS ONE. 2019 ;14(2):e0212801